Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 2/20 | 0.59 |
| ▸ | SYK | P43405 | 3/20 | 0.57 |
| ▸ | ABL1 | P00519 | 3/20 | 0.54 |
| ▸ | BCR | P11274 | 3/20 | 0.54 |
| ▸ | PRKCA | P17252 | 3/20 | 0.54 |
| ▸ | CTSC | P53634 | 1/20 | 0.53 |
| ▸ | CDK2 | P24941 | 1/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 6/20 | 0.50 |
| ▸ | BRAF | P15056 | 1/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.47 |
| ▸ | ITK | Q08881 | 3/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | PRKACA | P17612 | 1/20 | 0.47 |
| ▸ | PRKACG | P22612 | 1/20 | 0.47 |
| ▸ | PRKACB | P22694 | 1/20 | 0.47 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL84484 | 0.85 | EGFR (0.69) | IGF1RSYKCDK2GSK3BEGFR | |
| SCHEMBL15185760 | 0.84 | IGF1R (0.62) | IGF1RSYKABL1BCRPRKCA | |
| SCHEMBL84379 | 0.81 | AURKA (0.67) | — | |
| SCHEMBL84004 | 0.79 | CDK2 (0.54) | SYKCDK2GSK3BEGFRPIK3CA | |
| SCHEMBL16127509 | 0.78 | IGF1R (0.72) | IGF1RSYKCTSCCDK2EGFR | |
| SCHEMBL15181344 | 0.78 | PLK1 (0.49) | SYKABL1BCRCDK2GSK3B | |
| SCHEMBL15181351 | 0.77 | CDK5 (0.51) | SYKABL1CDK2GSK3BEGFR | |
| SCHEMBL8837875 | 0.76 | ABL1 (0.78) | IGF1RSYKABL1BCRPRKCA | |
| SCHEMBL16127518 | 0.75 | IGF1R (0.69) | IGF1RSYKABL1BCRPRKCA | |
| SCHEMBL1704 | 0.75 | ABL1 (0.65) | IGF1RSYKABL1BCRPRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | IGF1R 1812/4885SYK 1136/4885ABL1 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.